BioCryst Pharma (BCRX) Cash Flow Statement

Click line-items for a historical chart and %

Net loss	-50.64M
Depreciation and amortization	311K
Stock-based compensation expense	6.48M
Amortization of debt issuance costs	335K
Change in fair value of foreign currency derivative
Receivables from collaborations	275K
Inventories	-620K
Prepaid expenses and other current assets	667K
Deferred collaboration expense	43K
Accounts payable and accrued expenses
Interest payable	817K
Interest reserve
Deferred rent
Deferred collaboration revenue	-1.08M
Net cash used in operating activities
Acquisitions of furniture and equipment	-5.28M
Change in restricted cash	106K
Purchases of marketable securities	0
Sales and maturities of marketable securities	38.27M
Net cash used in investing activities
Exercise of stock options	204K
Employee stock purchase plan sales	300K
Purchases of treasury stock
Common stock issuance costs
Issuance of non-recourse notes payable
Debt issuance costs
Payment of foreign currency derivative collateral
Net cash provided by financing activities
Increase (decrease) in cash and cash equivalents	6.49M
Cash and cash equivalents at beginning of period	28.9M
Cash and cash equivalents at end of period	35.39M

Entities mentioned with BCRX

View All Entities